目次

Table of Content

1. Introduction To OX40/OX40L Pathway
1.1 Background Of OX40/OX40L Pathway
1.2 Significance In Immunotherapy
1.3 OX40/OX40L As Disease Biomarkers

2. Targeting The OX40/OX40L Pathway In Therapy
2.1 OX40/OX40L Agonism
2.2 OX40/OX40L Antagonism
2.3 Targeting Approaches and Mechanisms Of Action
2.3.1 Antibodies
2.3.2 Nucleic Acids
2.3.3 Fusion Protein
2.3.4 Small Molecules
2.3.5 Peptides

3. Indications For OX40/OX40L Targeted Therapies
3.1 Cancer
3.1.1 Solid Tumors
3.1.2 Hematologic Malignancies
3.2 Infectious Diseases
3.3 Autoimmune and Inflammatory Diseases
3.4 Other Potential Indications

4. OX40/OX40L Targeted Combination Therapies

5. Global OX40/OX40L Targeted Therapy Clinical Trials Overview
5.1 By Phase
5.2 By Indication
5.3 By Company

6. Global OX40/OX40L Targeted Therapy Clinical Trials Insight By Company, Country, Indication and Phase
6.1 Preclinical
6.2 Phase
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III
6.7 Phase III

7. OX40/OX40L Targeted Therapy Development Platforms By Company

8. Global OX40/OX40L Targeted Therapy Market Outlook
8.1 Current Market Overview
8.2 Future Prospects

9. Global OX40/OX40L Targeted Therapy Market Dynamics
9.1 Growth Drivers and Opportunities
9.2 Challenges and Strategic Solutions

10. Competitive Landscape
10.1 AbCellera Biologics
10.2 Apogee Therapeutics
10.3 Amgen
10.4 Astria Therapeutics
10.5 Bio-Thera
10.6 Elpiscience
10.7 HiFiBiO Therapeutics
10.8 Inhibrx Biosciences
10.9 ImageneBio
10.10 Kyowa Kirin
10.11 Navigator Medicines
10.12 Pfizer
10.13 Psivant Therapeutics
10.14 Sanofi
10.15 Shanghai Henlius Biotech

List of Figures
Figure 1-1: OX40/OX40L Pathway
Figure 1-2: OX40 In T Cell Subset Differentiation
Figure 1-3: OX40/OX40L Signaling Pathway In Disease
Figure 2-1: OX40 Agonism - Mechanism Of Action On T Cells
Figure 2-2: OX40 Agonism - Potential For Immunotherapy Across Diseases
Figure 2-3: OX40 Antagonism - Mechanism Of Action
Figure 2-4: Types Of OX40 Targeting Antibodies
Figure 2-5: Nanobodies Targeting OX40 - A Novel Approach
Figure 2-6: Nucleic Acid-Based Therapies Targeting OX40/OX40L
Figure 2-7: Fusion Proteins Targeting OX40/OX40L - Advantages
Figure 2-8: Small Molecules Targeting OX40-OX40L - Mechanism Of Action
Figure 2-9: Bicycle Peptides Targeting OX40 - Mechanism Of Action
Figure 3-1: HexAgon-HN Phase 2/3 (NCT06295731) Study - Initiation and Completion Year
Figure 3-2: BAT-6026-001-CR Phase 1 (NCT05105971) Study - Initiation and Completion Year
Figure 3-3: HFB-301001-01 Phase 1 (NCT05229601) Study - Initiation and Completion Year
Figure 3-4: FT04CARCIK Phase 1/2 (NCT05869279) Study - Initiation and Completion Year
Figure 3-5: LY007C1101 Phase 1 (NCT06364852) Study - Initiation and Completion Year
Figure 3-6: HLX51-FIH101 Phase 1 (NCT05788107) Study - Initiation and Completion Year
Figure 3-7: ROCKET-ASCEND Phase 3 (NCT05882877) Study - Initiation and Completion Year
Figure 3-8: ROCKET-Outpost Phase 3 (NCT06224192) Study - Initiation and Completion Year
Figure 3-9: RIVER-AD Phase 2/3 (NCT05492578) Study - Initiation and Completion Year
Figure 3-10: HLX51-FIH101 Phase 1 (NCT05788107) Study - Initiation and Completion Year
Figure 5-1: Global- OX40/OX40L Targeted Therapies In Clinical Trials By Phase, 2025 -2026
Figure 5-2: Global- OX40/OX40L Targeted Therapies In Clinical Trials By Indication, 2025 - 2026
Figure 5-3: Global - OX40/OX40L Targeted Therapies In Clinical Trials By Company, 2025 - 2026
Figure 7-1: ADAPTIR Bispecific
Figure 7-2: ADAPTIR - APVO603
Figure 7-3: Genmab - HexaBody
Figure 7-4: Inhibrx - sdAb Features
Figure 7-5: Conventional vs. sdAb Structure
Figure 7-6: INBRX-106 - Features
Figure 8-1: Global OX40/OX40L Targeting Therapy Market - Future Prospects
Figure 9-1: Global OX40/OX40L Targeting Therapy Market - Drivers and Opportunities
Figure 9-2: Global OX40/OX40L Targeting Therapy Market - Challenges and Strategic Solutions

List Of Tables
Table 1-1: OX40/OX40L As Prognostic Biomarker In Diseases
Table 2-1: Challenges Of OX40 Agonism - Risks and Optimizations
Table 4-1: OX40/OX40L Targeting Combination Therapies In Clinical Trials